US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Monkeypox Concept

1,509.95

-31.5625-2.05%

Number of Gainers:- -

Number of Losers:10

Number of Flat:1

PE:- -

High:1,550.79

Open:1,541.45

Low:1,503.86

Close:1,541.52

Loading ...

Gilead Sciences Advances Pediatric Hepatitis B Treatment with TAF Study Update

FDA Approves New Biktarvy Indication for Treatment-Experienced People With HIV Restarting Antiretroviral Therapy, Announces Gilead Sciences Inc

Idorsia H1 Net Income CHF 52 Million

Idorsia Ltd. Publishes Investor Presentation on Advancing Towards Profitability and Strategic Priorities

Gilead Sciences Inc. CEO Daniel O'Day Reports Disposal of Common Shares

Hookipa Pharma Inc. Conducted Special Stockholder Meeting to Vote on Key Proposals

Tonix Pharmaceuticals Unveils Presentation on TNX-1500 for Organ Transplant Rejection and Autoimmune Disorders

Virax Biolabs Appoints Iain Miller, PhD as Independent Director, Succeeding Yair Erez, to Propel Commercial Strategy

Virax Biolabs Appoints Iain Miller, Phd as Independent Director to Accelerate Commercial Strategy

THOMSON REUTERS

SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

BRIEF-Geovax Labs To Initiate Phase 3 Trial In second half of 2026

GeoVax Labs Inc - to Initiate Phase 3 Trial in 2H 2026 - SEC Filing

THOMSON REUTERS

Why Gilead Sciences Stock Slipped Today

Emergent BioSolutions Drops Amid Volume Spike, Last Down 5.8%

THOMSON REUTERS

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives

Gilead Sciences Stock Surges Amid Promising Trials

The Trader: GM Is Loading Up on Its Own Shares. Investors Should Follow Suit. -- Barron's

Why Gilead Sciences Stock Just Popped

BRIEF-EMA's CHMP Starts Review Of Tecovirimat SIGA

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4583/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"Monkeypox Concept","latestPrice":1509.9528,"timestamp":1753991999999,"preClose":1541.5153,"halted":0,"volume":25195686,"delay":0,"changeRate":-0.020475,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-31.5625,"latestTime":"07-31 16:00:00 EDT","open":1541.4458,"high":1550.7893,"low":1503.8562,"amount":1231094706.401991,"amplitude":0.030446,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1754035200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.015533,"peRate":62.614389,"turnoverRate":0.00939,"increases":0,"decrements":10,"flats":1,"marketCap":169829199635,"floatMarketCap":169128070697.25},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","high":1550.7893,"amplitude":0.030446,"preClose":1541.5153,"low":1503.8562,"pbRate":"4.015533","latestPrice":1509.9528,"volume":25195686,"delay":0,"open":1541.4458,"prevYearClose":1284.7982,"prevWeekClose":1563.1393,"prevMonthClose":1508.2938,"prevQuarterClose":1508.2938,"fiveDayClose":1532.325,"twentyDayClose":1516.9581,"sixtyDayClose":1409.4836,"secType":"PLATE","market":"US","turnoverRate":0.00939,"peRate":62.614389,"marketCap":169829199635,"floatMarketCap":169128070697.25,"timestamp":1753991999999,"nameCN":"Monkeypox Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4583\",,,,undefined,":{"bkCode":"BK4583","up":0,"down":10,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4583\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2556320448","title":"Gilead Sciences Advances Pediatric Hepatitis B Treatment with TAF Study Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2556320448","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556320448?lang=en_us&edition=fundamental","pubTime":"2025-08-01 00:18","pubTimestamp":1753978738,"startTime":"0","endTime":"0","summary":"Gilead Sciences (($GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Gilead Sciences is conducting a cl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gilead-sciences-advances-pediatric-hepatitis-b-treatment-with-taf-study-update?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gilead-sciences-advances-pediatric-hepatitis-b-treatment-with-taf-study-update?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","BK4578","LU1430594728.SGD","LU1585245621.USD","IE0002270589.USD","LU1066051498.USD","BK4566","BK4550","BK4585","IE00B19Z3B42.SGD","SG9999015952.SGD","LU0234570918.USD","LU2468319806.SGD","LU0058720904.USD","LU2087621335.USD","SG9999015978.USD","BK4139","IE00B3T34201.USD","LU0320765992.SGD","SG9999015945.SGD","IE00B19Z3581.USD","BK4532","BK4588","LU0109394709.USD","LU0889565916.HKD","GILD","IE00BKVL7J92.USD","LU1674673691.USD","LU2089984988.USD","LU1066053197.SGD","IE00BZ1G4Q59.USD","LU1571399168.USD","SG9999015986.USD","LU1674673428.USD","LU1839511570.USD","IE00BSNM7G36.USD","IE00B7SZLL34.SGD","LU0823416689.USD","LU1778281490.HKD","LU2324357040.USD","LU0289739699.SGD","BK4583"],"gpt_icon":0},{"id":"2555078865","title":"FDA Approves New Biktarvy Indication for Treatment-Experienced People With HIV Restarting Antiretroviral Therapy, Announces Gilead Sciences Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2555078865","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555078865?lang=en_us&edition=fundamental","pubTime":"2025-07-31 06:50","pubTimestamp":1753915807,"startTime":"0","endTime":"0","summary":"FDA Approves New Biktarvy Indication for Treatment-Experienced People With HIV Restarting Antiretroviral Therapy, Announces Gilead Sciences Inc. Gilead Sciences Inc. has announced that the U.S. Food and Drug Administration  has approved a new indication for their HIV treatment, Biktarvy. The approval expands the use of Biktarvy to include people with HIV who have a history of antiretroviral treatment, are not virologically suppressed, and are restarting therapy. This new indication addresses a significant public health need by offering a treatment option for individuals who have interrupted their HIV care and are not currently achieving viral suppression. The decision was based on robust evidence from studies demonstrating Biktarvy's effectiveness in achieving rapid and durable viral suppression, as well as its strong safety profile.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDL7qDGdp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673428.USD","IE00BSNM7G36.USD","LU0823416689.USD","BK4588","LU2468319806.SGD","BK4550","LU0058720904.USD","LU0289739699.SGD","LU2324357040.USD","IE00B7SZLL34.SGD","SG9999015952.SGD","LU1585245621.USD","BK4139","SG9999015978.USD","LU0234570918.USD","IE0002270589.USD","LU1674673691.USD","LU1066051498.USD","BK4585","LU2089984988.USD","BK4532","GILD","LU2087621335.USD","LU0109394709.USD","BK4566","SG9999015945.SGD","LU1066053197.SGD","BK4578","LU1430594728.SGD","BK4583","SG9999015986.USD","IE00B19Z3581.USD","IE00BKVL7J92.USD","LU1839511570.USD","LU1571399168.USD","IE00B19Z3B42.SGD","LU1778281490.HKD","LU0320765992.SGD","IE00BZ1G4Q59.USD","LU0889565916.HKD","IE00B3T34201.USD","BK4568"],"gpt_icon":0},{"id":"2555092802","title":"Idorsia H1 Net Income CHF 52 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2555092802","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555092802?lang=en_us&edition=fundamental","pubTime":"2025-07-30 13:14","pubTimestamp":1753852477,"startTime":"0","endTime":"0","summary":"July 30 (Reuters) - IDORSIA LTD ::*H1 NET INCOME CHF 52 MILLION*H1 EPS CHF 0.26*H1 REVENUE CHF 131 MILLION*H1 EBIT CHF 64 MILLION*H1 BASIC EPS CHF 0.26*CASH RUNWAY EXTENDED TO END OF 2026 - ON TRACK T","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nRSD7y0VLH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4583","BK4588","BK4007","LU1839511570.USD","VTRS","LU2087621335.USD"],"gpt_icon":0},{"id":"2555094447","title":"Idorsia Ltd. Publishes Investor Presentation on Advancing Towards Profitability and Strategic Priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2555094447","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555094447?lang=en_us&edition=fundamental","pubTime":"2025-07-30 13:04","pubTimestamp":1753851881,"startTime":"0","endTime":"0","summary":"Idorsia Ltd. has released its half-year financial report for 2025, highlighting significant advancements towards profitability. The company reported increased sales while materially lowering operational expenses. As of June 30, 2025, Idorsia's liquidity is expected to sustain operations until the end of 2026. The financial results reflect a US GAAP profitability driven by the Viatris deal. Idorsia continues to focus on unlocking the full value of QUVIVIQ, expanding strategic partnerships, and advancing its differentiated pipeline assets. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Idorsia Ltd. published the original content used to generate this news brief on July 30, 2025","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDL2NC0cQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4007","BK4588","LU1839511570.USD","VTRS","LU2087621335.USD","BK4585"],"gpt_icon":0},{"id":"2555061159","title":"Gilead Sciences Inc. CEO Daniel O'Day Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2555061159","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555061159?lang=en_us&edition=fundamental","pubTime":"2025-07-30 04:55","pubTimestamp":1753822544,"startTime":"0","endTime":"0","summary":"Daniel Patrick O'Day, Chairman & CEO of Gilead Sciences Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nNDL1P2HRM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","BK4568","IE00B7SZLL34.SGD","IE00BSNM7G36.USD","LU2087621335.USD","LU2324357040.USD","BK4532","SG9999015986.USD","BK4588","LU1585245621.USD","BK4578","LU0320765992.SGD","LU1066051498.USD","LU2468319806.SGD","IE00BKVL7J92.USD","BK4585","LU0058720904.USD","SG9999015945.SGD","SG9999015952.SGD","IE00B19Z3581.USD","IE00BZ1G4Q59.USD","LU0889565916.HKD","BK4583","LU1674673428.USD","LU0289739699.SGD","BK4139","LU0823416689.USD","LU0109394709.USD","LU1430594728.SGD","IE00B19Z3B42.SGD","LU1839511570.USD","LU2089984988.USD","LU1674673691.USD","BK4550","IE00B3T34201.USD","LU1066053197.SGD","IE0002270589.USD","LU1778281490.HKD","BK4566","LU1571399168.USD","GILD","SG9999015978.USD"],"gpt_icon":0},{"id":"2555066789","title":"Hookipa Pharma Inc. Conducted Special Stockholder Meeting to Vote on Key Proposals","url":"https://stock-news.laohu8.com/highlight/detail?id=2555066789","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555066789?lang=en_us&edition=fundamental","pubTime":"2025-07-30 04:02","pubTimestamp":1753819328,"startTime":"0","endTime":"0","summary":"Hookipa Pharma Inc. held a special meeting of stockholders on July 29, 2025. During the meeting, stockholders approved the sale of certain assets of the company pursuant to an Asset Purchase Agreement with Gilead Sciences, Inc. Additionally, the liquidation and dissolution of the company, as outlined in the Plan of Dissolution, received approval. The proposal to adjourn the meeting, if necessary to solicit additional proxies, was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hookipa Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 29, 2025, and is solely re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nNDL2HbbVf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","LU1585245621.USD","BK4588","IE0002270589.USD","LU0289739699.SGD","IE00B19Z3B42.SGD","LU0058720904.USD","SG9999015945.SGD","BK4585","LU0823416689.USD","SG9999015986.USD","LU0889565916.HKD","LU1674673691.USD","BK4532","BK4505","LU1839511570.USD","LU2324357040.USD","IE00B19Z3581.USD","BK4139","LU1674673428.USD","LU1778281490.HKD","LU2468319806.SGD","IE00B7SZLL34.SGD","GILD","LU2089984988.USD","HOOK","IE00BSNM7G36.USD","LU1430594728.SGD","LU0320765992.SGD","LU1066053197.SGD","SG9999015978.USD","SG9999015952.SGD","BK4568","IE00B3T34201.USD","IE00BZ1G4Q59.USD","BK4566","LU0109394709.USD","IE00BKVL7J92.USD","LU1571399168.USD","BK4550","BK4578","LU1066051498.USD","BK4583","LU2087621335.USD"],"gpt_icon":0},{"id":"2555063177","title":"Tonix Pharmaceuticals Unveils Presentation on TNX-1500 for Organ Transplant Rejection and Autoimmune Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2555063177","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555063177?lang=en_us&edition=fundamental","pubTime":"2025-07-30 01:14","pubTimestamp":1753809281,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals Holding Corp. has provided an update on their investigational new biologic, TNX-1500, which is designed to address organ transplant rejection and autoimmune disorders. TNX-1500 is a third-generation anti-CD40L monoclonal antibody, re-engineered to enhance Fc receptor modulation while maintaining FcRn function. The company has completed Phase 1 studies and is preparing to initiate Phase 2 studies in kidney transplant recipients. Potential future indications include Sjgren's Syndrome and Systemic Lupus Erythematosus, among others. Collaborations are ongoing with institutions for heart, kidney, and bone marrow transplantation research in non-human primates. TNX-1500 has not yet been approved for any indication. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nNDL4hqSct:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","TNXP","BK4139"],"gpt_icon":0},{"id":"2555053015","title":"Virax Biolabs Appoints Iain Miller, PhD as Independent Director, Succeeding Yair Erez, to Propel Commercial Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2555053015","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555053015?lang=en_us&edition=fundamental","pubTime":"2025-07-29 19:35","pubTimestamp":1753788956,"startTime":"0","endTime":"0","summary":"Virax Biolabs Group Ltd. announced the appointment of Iain Miller, PhD as an Independent Director to its Board of Directors, effective July 29, 2025. Dr. Miller succeeds Yair Erez, who is stepping down from the Board. Dr. Miller brings extensive experience in diagnostics and MedTech sectors, having held senior roles at GE Healthcare, bioMérieux, and Massachusetts General Hospital. His expertise is expected to contribute to Virax's commercial strategy as the company expands its immune profiling platform.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via PR Newswire  on July 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nNDL54bFTV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRAX","LU0689626769.HKD","BK4583","GEHC","LU0124676726.USD","BK4588","BK4082","BK4175","BK4585"],"gpt_icon":0},{"id":"2555530220","title":"Virax Biolabs Appoints Iain Miller, Phd as Independent Director to Accelerate Commercial Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2555530220","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555530220?lang=en_us&edition=fundamental","pubTime":"2025-07-29 19:35","pubTimestamp":1753788942,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nTUA1DYGWQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4175","BK4583","VRAX"],"gpt_icon":0},{"id":"2555056900","title":"SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2555056900","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555056900?lang=en_us&edition=fundamental","pubTime":"2025-07-29 19:30","pubTimestamp":1753788600,"startTime":"0","endTime":"0","summary":"NEW YORK, July  29, 2025  (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conferen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/29/3123132/9738/en/SIGA-to-Host-Business-Update-Call-on-August-5-2025-Following-Release-of-Second-Quarter-2025-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4583","BK4218","BK4007","HST","SIGA","BK4585","BK4181"],"gpt_icon":0},{"id":"2555153032","title":"BRIEF-Geovax Labs To Initiate Phase 3 Trial In second half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2555153032","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555153032?lang=en_us&edition=fundamental","pubTime":"2025-07-29 18:14","pubTimestamp":1753784067,"startTime":"0","endTime":"0","summary":"BRIEF-Geovax Labs To Initiate Phase 3 Trial In second half of 2026 July 29  - GeoVax Labs Inc GOVX.O:GEOVAX LABS INC - TO INITIATE PHASE 3 TRIAL IN 2H 2026 - SEC FILINGGEOVAX LABS INC - GEO-MVA RECEIVES FAVORABLE EUROPEAN REGULATORY GUIDANCE - SEC FILINGSource text: [ID:n0001437749-25-023689]Further company coverage: GOVX.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nFWN3TQ0PC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4139","GOVX"],"gpt_icon":0},{"id":"2555032645","title":"GeoVax Labs Inc - to Initiate Phase 3 Trial in 2H 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2555032645","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555032645?lang=en_us&edition=fundamental","pubTime":"2025-07-29 18:08","pubTimestamp":1753783692,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nFWN3TQ0PC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GOVX","BK4583"],"gpt_icon":0},{"id":"2555701618","title":"Why Gilead Sciences Stock Slipped Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2555701618","media":"Motley Fool","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555701618?lang=en_us&edition=fundamental","pubTime":"2025-07-29 04:32","pubTimestamp":1753734720,"startTime":"0","endTime":"0","summary":"Changes in a federal healthcare authority could negatively impact one of the company's important businesses.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/07/28/why-gilead-sciences-stock-slipped-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["IE00B19Z3B42.SGD","LU1839511570.USD","IE00BZ1G4Q59.USD","LU0058720904.USD","BK4583","BK4578","BK4568","SG9999015986.USD","BK4585","LU1674673691.USD","SG9999015952.SGD","LU0234570918.USD","GILD","BK4566","LU1066053197.SGD","SG9999015978.USD","BK4139","BK4550","LU0320765992.SGD","LU1674673428.USD","IE0002270589.USD","LU1430594728.SGD","IE00B19Z3581.USD","IE00B3T34201.USD","LU1571399168.USD","LU0289739699.SGD","LU2324357040.USD","IE00BKVL7J92.USD","LU2468319806.SGD","IE00BSNM7G36.USD","LU0109394709.USD","BK4009","BK4588","LU1585245621.USD","BK4532","HHS","LU1778281490.HKD","LU0889565916.HKD","LU2087621335.USD","IE00B7SZLL34.SGD","SG9999015945.SGD","LU0823416689.USD","LU1066051498.USD","LU2089984988.USD"],"gpt_icon":0},{"id":"2555706272","title":"Emergent BioSolutions Drops Amid Volume Spike, Last Down 5.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555706272","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555706272?lang=en_us&edition=fundamental","pubTime":"2025-07-29 03:35","pubTimestamp":1753731315,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nL6N3TP0UB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EBS","BK4139","BK4583"],"gpt_icon":0},{"id":"2554774377","title":"New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox","url":"https://stock-news.laohu8.com/highlight/detail?id=2554774377","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554774377?lang=en_us&edition=fundamental","pubTime":"2025-07-28 20:50","pubTimestamp":1753707000,"startTime":"0","endTime":"0","summary":"Ongoing mpox outbreak continues to be a global health threat and is driving need for greater therapeutic research and innovationGAITHERSBURG, Md., July  28, 2025  (GLOBE NEWSWIRE) -- Emergent BioSolut","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/28/3122491/33240/en/New-Publication-in-Expert-Review-of-Anti-infective-Therapy-Evaluates-Brincidofovir-as-Potential-Antiviral-Treatment-for-Mpox.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EBS","BK4583","BK4139"],"gpt_icon":0},{"id":"2554301774","title":"Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2554301774","media":"GlobeNewswire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554301774?lang=en_us&edition=fundamental","pubTime":"2025-07-28 20:50","pubTimestamp":1753707000,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., July  28, 2025  (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announces its recognition of the U.S. House of Representatives for adding over-the-counter (OTC) nal","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/28/3122490/33240/en/Emergent-Applauds-Availability-of-Over-the-Counter-Naloxone-in-U-S-House-of-Representatives.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4583","EBS"],"gpt_icon":0},{"id":"2554194317","title":"Gilead Sciences Stock Surges Amid Promising Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2554194317","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554194317?lang=en_us&edition=fundamental","pubTime":"2025-07-26 22:01","pubTimestamp":1753538517,"startTime":"0","endTime":"0","summary":"Gilead Sciences ( ($GILD) ) has risen by 7.31%. Read on to learn why. Gilead Sciences has seen a notable increase in its stock price, rising by 7.3...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/gilead-sciences-stock-surges-amid-promising-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/gilead-sciences-stock-surges-amid-promising-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0234570918.USD","LU2468319806.SGD","BK4532","LU2087621335.USD","IE0002270589.USD","BK4139","BK4578","LU1430594728.SGD","SG9999015952.SGD","IE00B7SZLL34.SGD","LU1066051498.USD","BK4583","LU2324357040.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","LU1839511570.USD","LU1674673691.USD","BK4585","LU1066053197.SGD","IE00B19Z3581.USD","BK4588","LU0889565916.HKD","GILD","LU1571399168.USD","LU1585245621.USD","LU0109394709.USD","LU0289739699.SGD","SG9999015986.USD","SG9999015945.SGD","BK4550","BK4566","LU0058720904.USD","LU1778281490.HKD","IE00B19Z3B42.SGD","LU2089984988.USD","SG9999015978.USD","BK4568","IE00BKVL7J92.USD","LU0320765992.SGD","IE00B3T34201.USD","LU0823416689.USD","LU1674673428.USD"],"gpt_icon":0},{"id":"2554779072","title":"The Trader: GM Is Loading Up on Its Own Shares. Investors Should Follow Suit. -- Barron's","url":"https://stock-news.laohu8.com/highlight/detail?id=2554779072","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554779072?lang=en_us&edition=fundamental","pubTime":"2025-07-26 09:30","pubTimestamp":1753493400,"startTime":"0","endTime":"0","summary":"General Motors is too darn cheap -- and the company has a solution to that problem investors should take note of.Between its earnings and President Donald Trump's trade deal with Japan, it was a wild week for GM. On Tuesday, it reported better-than-expected second-quarter results, but the stock promptly dropped 8.1% in response. Then shares jumped 8.7% on Wednesday, despite Trump announcing a trade deal with Japan that lowered import tariffs on cars from that nation to 15% from 25%.The recent stop-and-start pacing of share buybacks has been a problem. GM paused its repurchases in the second quarter amid tariff uncertainty. It re-entered the market in July, according to Chief Financial Officer Paul Jacobson. GM still has $4.3 billion in repurchase authorizations remaining, not insignificant for a company with a market value of roughly $50 billion. And despite lower profits due to tariffs, it is expected to generate about $11 billion in free cash flow over the coming 12 mo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770308.USD","LU0006061336.USD","BK4099","LU1839511570.USD","LU0130518102.USD","LU0648001328.SGD","BK4559","BK4596","LU0070302665.USD","LU0320765489.SGD","LU0130103400.USD","LU1201861249.SGD","VTRS","LU0477156953.USD","ISBC","BK4588","LU0648000940.SGD","BK4566","LU0072461881.USD","LU0980610538.SGD","BK4583","LU0130102774.USD","LU0208291251.USD","LU0345770993.USD","BK4585","BK4574","LU2087621335.USD","GM","BK4007","BK4561","LU1201861165.SGD","BK4211","LU0162691827.USD","LU0211331839.USD","LU0130517989.USD","BK4555","LU0477156797.USD","BK4516"],"gpt_icon":1},{"id":"2554799441","title":"Why Gilead Sciences Stock Just Popped","url":"https://stock-news.laohu8.com/highlight/detail?id=2554799441","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554799441?lang=en_us&edition=fundamental","pubTime":"2025-07-26 01:37","pubTimestamp":1753465020,"startTime":"0","endTime":"0","summary":"Gilead stock is flashing \"buy\" in bright green letters.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/07/25/why-gilead-sciences-stock-just-popped/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU0823416689.USD","IE00B19Z3B42.SGD","LU1778281490.HKD","IE00B7SZLL34.SGD","LU1585245621.USD","LU0234570918.USD","LU1430594728.SGD","GILD","LU1839511570.USD","BK4585","LU0889565916.HKD","BK4588","BK4566","BK4139","IE00BSNM7G36.USD","BK4583","LU1066053197.SGD","IE00B19Z3581.USD","LU1066051498.USD","BK4578","IE00BZ1G4Q59.USD","IE00B3T34201.USD","LU2468319806.SGD","LU2089984988.USD","SG9999015986.USD","LU0109394709.USD","SG9999015945.SGD","LU0058720904.USD","LU1571399168.USD","SG9999015952.SGD","LU0289739699.SGD","BK4532","BK4568","IE00BKVL7J92.USD","SG9999015978.USD","LU1674673428.USD","LU2087621335.USD","IE0002270589.USD","BK4550","LU1674673691.USD","LU0320765992.SGD","LU2324357040.USD"],"gpt_icon":0},{"id":"2554769123","title":"BRIEF-EMA's CHMP Starts Review Of Tecovirimat SIGA","url":"https://stock-news.laohu8.com/highlight/detail?id=2554769123","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554769123?lang=en_us&edition=fundamental","pubTime":"2025-07-25 18:53","pubTimestamp":1753440780,"startTime":"0","endTime":"0","summary":"BRIEF-EMA's CHMP Starts Review Of Tecovirimat SIGAJuly 25  - EMA's CHMP:EMA'S CHMP-STARTED REVIEW OF TECOVIRIMAT SIGA TO CONSIDER EMERGING DATA FROM RECENT CLINICAL TRIALS SUGGESTING LACK OF EFFECTIVENESS IN MPOX TREATMENTFurther company coverage: SIGA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250725:nFWN3TM11F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SIGA","BK4007","BK4583"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":56,"code":"91000000","status":"200"}]}}